1. Different in vivo properties of three new inhibitors of catechol 0- methyltransferase in the rat;Mannisto, P.T.; Tuomainen, P.; Tuominen, R.K.,1992
2. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor Entacapone;Nissinen, E.; Linden, I.B.; Schultz, E.; Pohto, P.;Naunyn Schmiedeberg's Arch Pharmnacol,1992
3. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease;Myllyla, VV, Sotaniemi; KA, Illi; A, Suominen; K, Keranen; T.;Eur_J Cltn Pharmacol
4. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients;Kaakkola, S.; Teravainen, H.; Ahtila, S.; Rita, H.; Gordin, A.;Neurology,1994
5. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients;Nutt, J.G.; Woodward, W.R.; Beckner, R.M.;Neurology,1994